App-Quantinova.ai

Vedolizumab for the treatment of chronic pouchitis: the Edinburgh experience

S Cesano - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Pouchitis

Entyvio

Malnutrition rates are highest in pre-surgical Crohn’s disease when compared with active CD, CD in remission and UC in remission

A Sandall - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI

B E Sands - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Ustekinumab

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data

T Card - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Entyvio

Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission

D T Rubin - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Tasocitinib

Immunogenicity of a proposed adalimumab biosimilar, FKB327, and the reference product in patients with rheumatoid arthritis

R Alten - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Adalimumab biosimilar

Comparative efficacy of anti-tumour necrosis factor agents and vedolizumab in ulcerative colitis

S Subramanian - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Entyvio

Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: a systematic review and meta-analysis

T Thomas - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Primary sclerosing cholangitis

N/A

Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1

M Rosario - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

LDP 02

Multinational comparisons of practices in overseas travel in Crohn’s disease and ulcerative colitis

K Greveson - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study

W J Sandborn - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)

I Visuri - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Long-term function after transanal vs. transabdominal ileal pouch-anal anastomosis for ulcerative colitis: a multi-centre cohort study

P Chandrasinghe - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Association of vedolizumab levels with clinical and biochemical markers of inflammation during maintenance therapy in inflammatory bowel disease

N Plevris - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Entyvio

Analysis of UC colectomy rates in pre- and post-biologic era in South-East Scotland

P Jenkinson - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multi-centre case series

F M Phillips - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Entyvio

Higher serum golimumab concentrations are significantly associated with combined clinical-biochemical remission during maintenance therapy: results from the GO-LEVEL study

M Samaan - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

golimumab

Tacrolimus suppositories: a safe and effective treatment for treatment-refractory proctitis

R Smith - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Tacrolimus

INSPIRE: design and implementation aspects of a registry of complex perianal fistulas in Crohn’s disease patients treated with darvadstrocel

O Zmora - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

CX601

Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on infliximab

D Yerlioglu - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Infliximab

Filters

45280 Abstracts